Plasmablastic lymphoma
MONDO:0017347An aggressive diffuse large B-cell lymphoma frequently arising in the setting of HIV infection and characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells. Sites of involvement include the oral cavity, sinonasal cavity, skin, soft tissues, gastrointestinal tract, and bone.
Also known as: PBL, Plasmablastic lymphoma, PLBL
2016 clinical trials for this condition and its sub-types, 20 tagged with Plasmablastic lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Experimental drug shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tests a drug called CPI-613 in people with relapsed or hard-to-treat Burkitt lymphoma or high-grade B-cell lymphoma. About 24 participants aged 12 and older who have not responded to at least one prior treatment will receive the drug. The goal is to see if the drug can…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Shorter chemo shows promise for HIV patients with lymphoma
Disease control CompletedThis study tested a shorter course of a chemotherapy combination called EPOCH-R in 68 people with HIV and a type of lymphoma. The goal was to see if reducing the amount of chemotherapy could still control the cancer while causing less damage to the immune system. Participants rec…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
HIV-Fighting cells show promise in lymphoma treatment
Disease control CompletedThis study tested a new approach for people with both HIV and lymphoma. After high-dose chemotherapy and a stem cell transplant, participants received specially grown HIV-fighting immune cells (HST-NEETs). The goal was to see if giving these cells was feasible and if they could r…
Phase 2 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC